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Abstract  
A blue whiting (Micromesistius poutassou) protein hydrolysate generated using Alcalase 2.4L 
and Flavourzyme 500L and its simulated gastrointestinal digestion (SGID) sample was 
assessed for antidiabetic potential in vitro and in vivo. In addition to inhibiting dipeptidyl 
peptidase-IV (DPP–IV), the hydrolysates mediated insulin and glucagon-like peptide-1 (GLP-
1) release from BRIN-BD11 and GLUTag cells, respectively. No significant difference was 
observed in insulinotropic and DPP-IV inhibitory activity following SGID, while GLP-1 
secretion increased significantly (p<0.01). SGID resulted in a significant increase in membrane 
potential, intracellular calcium and cyclic AMP concentration (p<0.001) versus a glucose 
control, indicating that insulin secretion may be mediated by the KATP channel-dependent and 
the protein kinase A pathways. Additionally, acute (90-120 min) and persistent (4 h) glucose-
lowering effects of the blue whiting hydrolysate were observed in normal healthy mice. These 
results demonstrate that the blue whiting protein hydrolysate had significant metabolic effects 
relevant to glucose control in vivo.  
 
 
 
 
 
 
 
 
Keywords: blue whiting, protein hydrolysate, antidiabetic, functional food, amino acid 
analysis, peptide identification. 
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1. Introduction 
The global demand for high-quality protein is increasing. This is driven primarily by a growing 
world population, emerging economies in developing countries, increased urbanisation, 
recognition of the role of protein in a healthy diet and an increased need for protein intake by 
the elderly (UN, 2013). Exploitation of underutilised or low value fish species or side streams 
from existing food processing systems, which are currently used as animal and farmed 
fish/shellfish feed, is one approach for ensuring a sustainable protein supply in the future. In 
addition, a number of low value/underutilised fish species, which are now landed in significant 
quantities due to European Common Fisheries Policy reforms, are a rich source of bioactive 
protein hydrolysates/peptides and have potential applications as high value functional food 
ingredients. The recovery of protein and the subsequent generation of biofunctional peptide 
ingredients provide an opportunity for marine processors to add value to existing marine 
resources. Furthermore, the generation of hydrolysates with reduced immunoreactivity (e.g., 
hydrolysis of parvalbumin) can significantly increase the application of fish proteins as food 
ingredients (García-Moreno et al., 2017).  
With a protein content of approximately 18.6% (w/w), blue whiting (Micromesistius 
poutassou) represents one such marine source (Yoshie-Stark, Tsukamoto, Futagawa, Kubota, 
& Ogushi, 2009). Protein hydrolysates and peptides from blue whiting have shown satiating 
activity in vitro and in animal, as well as human studies (Cudennec, Fouchereau-Peron, Ferry, 
Duclos, & Ravallec, 2012; Duclos, 2013; La Rochelle, Courois, Cudennec, Fouchereau-Peron, 
& Ravallec-Ple, 2015; Nobile et al., 2016). Blue whiting hydrolysates have been reported to 
stimulate the secretion of the appetite supressing peptide glucagon-like peptide-1 (GLP-1) in 
vitro and in vivo. However, there is limited information in relation to the insulinotropic and 
antidiabetic potential of these protein hydrolysates (Cudennec et al., 2012; La Rochelle et al., 
2015; Nobile et al., 2016). Type 2 diabetes mellitus (T2DM), which accounts for approximately 
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90% of all cases of diabetes, is currently one of the fastest growing health problems worldwide. 
The estimated global occurrence of T2DM was 415 million people in 2015 with predictions 
that without appropriate intervention this could reach 642 million by 2040 (IDF Atlas, 2015). 
The increasing prevalence of T2DM and related complications places a significant economic 
burden on society in terms of direct healthcare and indirect societal costs. Current treatments 
for T2DM include the use of biguanides, meglitinides, sulphonylureas, thiazolidinediones, 
insulin, insulin analogues, sodium glucose co-transporter-2 (SGLT-2) inhibitors, incretin-
based therapies, DPP-IV and α-glucosidase inhibitors (Olokoba, Obateru, & Olokoba, 2012).  
The high cost and adverse side-effects associated with synthetic antidiabetic drugs supports an 
unmet need to identify natural biofunctional components for the prevention and improved 
management of T2DM. Health enhancing components such as peptides may play this role when 
used as part of a functional food-based dietary strategy. 
Dietary protein, protein hydrolysates, peptides and amino acids can beneficially regulate 
glycaemic control with the magnitude of the response differing significantly depending on the 
primary sequence of the peptides and amino acids generated during digestion (Newsholme & 
Krause, 2012; Oseguera-Toledo, de Mejía, Reynoso-Camacho, Cardador-Martínez, & Amaya-
Llano, 2014; Ranawana & Kaur, 2013). In previous studies, we have demonstrated that a 
salmon muscle protein hydrolysate generated with the food-grade proteolytic enzyme 
preparations Alcalase 2.4L and Flavourzyme 500L showed potent DPP-IV inhibitory activity 
in vitro (Neves, Harnedy, O’Keeffe, & FitzGerald, 2017). The present investigation was 
designed to assess the antidiabetic potential of a blue whiting protein hydrolysate generated 
with Alcalase 2.4L and Flavourzyme 500L in vitro, to determine what impact, if any, simulated 
gastrointestinal digestion (SGID) has on this activity and to determine the mechanism by which 
the hydrolysate mediates its antidiabetic activity. Additionally, the effects of the hydrolysate 
on glucose homeostasis were examined in normal healthy mice. 
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2. Materials and methods  
2.1. Materials and chemicals 
Abz-Gly-p-nitro-Phe-Pro-OH, Abz-Gly-OH*HCl, H-Gly-Pro-AMC (7-amino-4–methyl 
coumarin) and Diprotin A were from Bachem Feinchemikalien (Bubendorf, Switzerland). 
Corolase PP was provided by AB Enzymes (Darmstadt, Germany) and BC pepsin was kindly 
provided by Biocatalysts Ltd (Cardiff, Wales, United Kingdom). HPLC grade water and 
acetonitrile were from VWR International (Dublin, Ireland) and trinitrobenzenesulphonic acid 
(TNBS) reagent was from Medical Supply Co Ltd. (Dublin, Ireland). ESI low molecular mass 
tune mix was from Agilent Technologies (Cork, Ireland). Calcium chloride dihydrate 
(CaCl2×2H2O), D-glucose, HEPES, hydrochloric acid (HCl), magnesium sulphate 
(MgSO4×7H2O), potassium dihydrogen orthophosphate (KH2PO4), potassium chloride (KCl), 
sodium bicarbonate (NaHCO3) and sodium chloride (NaCl) were purchased from BDH 
Chemicals Ltd (Poole, Dorset, UK).  Fetal bovine serum (FBS), Hank’s buffered saline solution 
(HBSS 10× stock), penicillin-streptomycin (0.1g/L), RPMI-1640 culture media, Dulbecco’s 
modified Eagle’s medium (DMEM) containing high glucose and trypsin/EDTA (10×) were 
obtained from Gibco Life Technologies Ltd (Paisley, Strathclyde, UK).  Radio-labelled sodium 
iodide (Na 125I, IMS 100 mCi/mL stock) was purchased from Perkin Elmer (Buckinghamshire, 
UK). Rat insulin standard was purchased from Novo Industria, Copenhagen, Denmark. All 
other reagents including DPP-IV, from porcine kidney (≥10 units/mg protein), Alcalase® 2.4L 
and Flavourzyme® 500L were supplied by Sigma Chemical Company Ltd. (Wicklow, Ireland). 
Samples of minced blue whiting (Micromesistius poutassou) meat were kindly provided by the 
Killybegs Fishermen's Organisation, Killybegs, Co Donegal, Ireland through Bord Iascaigh 
Mhara (BIM, Ireland) and were stored at -20 ˚C.  
2.2. Generation of blue whiting hydrolysate by direct enzymatic hydrolysis  
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The minced blue whiting meat was suspended at 1:1.25 (w/v) in distilled water and 
homogenised at room temperature at 24,000 rpm for four × 15 sec durations (Ultra-Turrax® 
T25 Basic, IKA®, Staufen, Germany). Additional water was added following homogenisation 
to obtain a 6.00% (w/v) blue whiting protein suspension. The suspension was preheated to 50 
°C and adjusted to pH 7.0 and then hydrolysed with Alcalase 2.4L and Flavourzyme 500L at 
an enzyme:substrate (E:S) ratio of 0.74% (v/w) for both enzyme at 50 °C. The hydrolysis 
reaction was maintained at pH 7.0 using a pH-stat (842 Titrando, Metrohm, Switzerland). The 
enzymes were inactivated after 4 h by heating at 90 °C for 20 min. Peptides were then separated 
by filtration under vacuum using a Buchner funnel with Whatman grade 1 (11 µm) filter paper. 
The filtration step was repeated to remove any insoluble material. The filtrate containing the 
peptides was then freeze-dried (FreeZone 18L, Labconco, MO, USA) and stored at -20 °C. 
 
2.3. Simulated gastrointestinal digestion (SGID)  
SGID was performed as described by Walsh et al. (2004) with modifications. In brief, the 
hydrolysate (2.0% (w/v) protein equivalents) was incubated at 37 °C and pH 2 for 90 min with 
pepsin at an E:S of 2.5% (w/w). The pH of the samples were adjusted to pH 7 and subjected to 
heat inactivation at 90 °C for 20 min. The samples were then incubated for a further 150 min 
at 37 °C with Corolase PP (E:S of 1% (w/w)) and inactivated as described above. All samples 
were subsequently freeze-dried and stored at -20 °C. 
 
2.4. Quantification of DPP- IV inhibitory activity 
DPP-IV inhibition was determined as described by Harnedy et al (2015). All assays were 
performed in triplicate (n=3). Activity results were expressed as IC50 values (inhibitory 
concentration that inhibits DPP-IV by 50%) for three independent replicates (n=3). Diprotin A 
was used as a positive control.  
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2.5. In-vitro insulin secretion from BRIN‑BD11 cells 
The effect of the blue whiting hydrolysate and its SGID sample on in vitro insulin secretion 
from clonal pancreatic BRIN-BD11 was determined as previously described (McClenaghan et 
al., 1996). In brief, cells were seeded into 24-well plates (150,000 cells per well) and allowed 
to attach overnight at 37 °C. Following a pre-incubation step (40 min; 37 oC; 1.1 mM glucose) 
cells were incubated in the presence of 5.6 mM glucose and hydrolysate concentrations ranging 
from 0.039 - 2.500 mg/mL for 20 min at 37 °C. An aliquot (200 μL) of the buffer was then 
removed from each of the wells and stored at -20 °C prior to measurement of insulin by 
radioimmunoassay (RIA).  
 
2.6. In-vitro GLP-1 secretion  
The effect of the blue whiting hydrolysate and its SGID sample on GLP-1 secretion from 
murine GLUTag cells was determined as described previously (Ojo, Conlon, Flatt, & Abdel-
Wahab, 2013). In brief, cells were seeded (150,000 cells per well) on matrigel coated 24-well 
tissue culture plates and incubated overnight at 37 °C. After a pre-incubation step (40 min, 37 
°C), the cells were presented with the hydrolysates (2.5 mg/mL) prepared in 2 mM glucose and 
incubated for 2 h at 37 °C. The supernatant buffer was then removed and stored at -20 °C prior 
to measurement of GLP-1 concentration using a sandwich ELISA according to the 
manufacturer's instructions (GLP-1 Total ELISA, EZGLP-1T-36K, Millipore, MA, USA). 
 
2.7. Adipocyte differentiation and glucose uptake in-vitro 
The effect of the blue whiting hydrolysate on the enhancement of basal and insulin-stimulated 
glucose uptake was assessed in 3T3-L1 adipocytes. The 3T3-L1 adipocytes were acquired from 
American type culture collection (Manassas, Virginia, USA). Prior to analysis the cells were 
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seeded at a density of 35,000 cells/well and fed every 2 days with Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% (v/v) heat inactivated FBS until confluence. The 
cells were incubated in this media for a further 2 days and then differentiated in DMEM 
containing 10% FBS, 15 μg/mL insulin, 1 μM dexamethasone and 0.5 mM 3-isobutyl-l-
methylxanthine (IBMX). The cells were then cultured in DMEM containing 10% FBS and 15 
μg/mL of insulin. Following differentiation, cells were treated with 100 µL of the blue whiting 
hydrolysate or control that were supplemented in glucose-free culture medium containing 150 
µg/mL fluorescently-tagged glucose derivative (2-NBDG) and incubated for 20 min.  After 
incubation, the plate was then centrifuged (Beckman Instruments Inc., UK) for 5 min at 400 × 
g at room temperature. The supernatant was aspirated and cells were washed with 200 µL cell-
based assay buffer followed by further centrifugation for 5 min.  The wash buffer was removed 
and 100 µL of cell-based assay buffer was added to all wells and then the fluorescence was 
read immediately at 485 nm with emission measured at 535 nm using the FlexStation scanning 
fluorimeter (Molecular Devices, USA). Apigenin (50 µM) was used as a negative control. 
 
2.8. Mechanistic studies using BRIN-BD11 cells 
The effect of the blue whiting hydrolysate subjected to SGID (2.5 mg/ml) on changes in 
membrane potential and intracellular calcium concentration [Ca2+]i  were determined 
fluorimetrically utilizing monolayers of BRIN-BD11 cells and Flex membrane potential and 
calcium assay kits (Molecular Devices, Sunnyvale, CA, USA) as previously described 
(Srinivasan, Mechkarska, Abdel-Wahab, Flatt, & Conlon, 2013). Control incubations with 10 
mM KCl and 10 mM alanine in the presence of 5.6 mM glucose were performed. Fluorimetric 
data was acquired using a FlexStation scanning fluorimeter utilizing an integrated fluid transfer 
workstation (Molecular Devices, Sunnyvale, CA, USA). The effect of the blue whiting 
hydrolysate subjected to SGID on the production of cAMP was also assessed in BRIN-BD11 
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cells. Cells were seeded (150,000 cells per well) into 24-well plates and incubated overnight. 
Cells were then washed with HBSS buffer before incubation (20 min, 37 °C) with the blue 
whiting hydrolysate (2.5 mg/mL) in the presence of 200 μM IBMX. The medium was then 
removed, cells lysed and the concentration of cAMP in the cell lysates was determined using a 
cAMP detection kit (R&D Systems Parameter, Abingdon, UK). 
 
2.9. Protein quantification and physiscochemical characterisation  
The protein equivalent content of the blue whiting  protein hydrolysate and its SGID sample 
was determined by the macro-Kjeldahl procedure as described previously by Connolly, 
Piggott, and FitzGerald (2013) using a nitrogen to protein conversion factor of 6.25 
(Kristinsson & Rasco, 2000). 
The degree of hydrolysis (DH) was estimated by the TNBS method as described by  Le Maux 
et al. (2016) with absorbance readings taken at 350 nm. All samples were analysed in triplicate 
(n=3). The % DH was estimated using the following equation:  
 
% DH =  (AN2-AN1)/Npb × 100 
 
Where AN1 is the amino nitrogen content of 5.6 mg amino nitrogen/g protein recommended 
by Alder-Nissen (1979) when the source protein value is not known, AN2 is the amino nitrogen 
content of the hydrolysate (mg/g protein) and Npb is the nitrogen content of the peptide bonds 
in the protein substrate (102.3 for fish muscle, Alder-Nissen, 1979). The molecular mass 
distribution profiles of the blue whiting protein hydrolysate and SGID samples were 
determined by gel permeation-high performance liquid chromatography (GP-HPLC)  using the 
method described by Spellman et al. (2005).  
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2.10. Total and free amino acid composition 
Total and free amino acid analysis of the hydrolysate subjected to SGID was performed by 
external contract suppliers. In brief, for total amino acid analysis the sample was hydrolysed in 
6 N hydrochloric acid for 24 h at approximately 110 °C. Phenol and dithiodipropionic acid 
were added to the sample to prevent halogenation of tyrosine and convert both cystine and 
cysteine to S-2-carboxyethylthiocysteine, respectively. Hydrolysed samples were analyzed by 
HPLC after pre-injection derivatization. The primary amino acids were derivitized with o-
phthalaldehyde (OPA) and the secondary amino acids with 9-Fluorenylmethyl chloroformate 
(Fmoc-Cl). In brief for free amino acid analysis, the sample was deproteinised by mixing 24% 
(w/v) trichloroacetic acid (TCA) and sample 1:1, standing for 10 min and centrifuging at 14400 
× g (Microcentaur, MSE, UK) for 10 min. The supernatant was removed and mixed with 0.2 
M sodium citrate buffer, pH 2.2 to an approximate concentration of 250 nmol for each amino 
acid residue. Samples were then diluted 1 in 2 with the internal standard, norleucine, to give a 
final concentration of 125 nm/mL. Amino acids were quantified using a Jeol JLC-500/V amino 
acid analyser (Jeol (UK) Ltd., Herts, UK) fitted with a Jeol Na+ high performance cation 
exchange column. 
 
2.11. Peptide Identification 
The separation and identification of peptides in the blue whiting hydrolysate subjected to SGID 
was performed by UPLC-ESI-MS/MS using an ACQUITY UPLC (Waters, Milford, MA, 
USA) coupled to an Impact HD Ultra High Resolution (UHR) Q-TOF (Bruker Daltonics, 
Bremen, Germany). The hydrolysate sample (7µl of 0.1 mg mL-1 in mobile phase A (0.1% 
(v/v) formic acid (FA) in MS-grade H2O)) was passed through a 0.22 µm filter (Restek Ireland, 
Belfast, N. Ireland) and injected onto an Acquity BEH 300 C18 column (2.1 × 50 mm, 1.7 µm; 
Waters, Dublin, Ireland). Mobile phase B was 0.1% (v/v) FA in 80% ACN (v/v). Peptides were 
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separated as follows: 0–0.28 min: 0% B; 0.28-45 min: 0-80% B; 45-46 min: 80-100% B; 46-
48 min 100% B; 48-49 min: 100-50% B; 49-50 min 50% B; 50-51 min 50-0% B; 51-53 min 
0% B at a flow rate of 0.2 mL/min. The MS/MS methods used were as previously published in 
O'Keeffe and FitzGerald (2015) and O'Keeffe, Norris, Alashi, Aluko, and FitzGerald (2017). 
The MS was calibrated with ESI low concentration tune mix (Agilent) for the long peptide 
method and with sodium formate for the short peptide method. MS was performed in positive 
ion mode. MS/MS spectra were searched against a database (Chordata limited SwissProt) in 
addition to a de novo sequencing approach. Peptides ≥ 6 amino acids in length identified by de 
novo sequencing were searched for homology with fish proteins using the FASTAM tool 
(available at http://www.ebi.ac.uk/Tools/sss/fastm/). The sequences of 48 proteins from 
Micromesistius poutassou (blue whiting) were obtained from the UniprotKB database and were 
entered into an ‘in-house’ database and short (<5 amino acids) peptides identified by de novo 
sequencing were searched for homology within these proteins. 
 
2.12. Oral glucose tolerance test in NIH Swiss mice  
The acute glucose-lowering and insulin releasing properties of the blue whiting protein 
hydrolysate was determined in vivo using 10-12 week old male NIH Swiss mice (Harlan, UK). 
In brief, age-matched groups (n=8) of overnight fasted mice received an oral gavage of either 
glucose alone (18.8 mmol/kg body weight) or in combination with the blue whiting hydrolysate 
(100 mg/kg body weight). All animal experiments were carried out in accordance with the UK 
Animals (Scientific Procedures) Act 1986 and EU laws. Blood samples were collected at 0, 15, 
30, 60, 90 and 120 min for the acute effect study and 4, 8 and 12 h for the delayed persistent 
effect study, post administration from the tail vein of conscious mice and added into chilled 
fluoride/heparin micro-centrifuge tubes (Sarstedt, Numbrecht, Germany). The blood samples 
were centrifuged at 13,000 rpm for 3 min (Universal 320, Hettich Zentrifugen, Germany). 
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Blood glucose concentrations were measured using an Ascencia Contour blood glucose meter 
(Bayer Healthcare, Newbury, UK). Plasma insulin was determined using a modified dextran-
coated charcoal RIA (Flatt & Bailey, 1981).  
 
2.13. Statistical analysis 
SPSS (version 20, IBM Inc., Chicago, IL, USA) was utilized to perform statistical analysis on 
the degree of hydrolysis and DPP-IV inhibition data. Statistical significance at a level of p<0.05 
was determined using one-way analysis of variance (ANOVA) followed by Tukey’s and 
Games–Howell post-hoc tests, where applicable. All other results were analysed using 
GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Statistical 
analyses were performed using the Students unpaired t-test. Where appropriate, data were 
compared using one-way and two-way analysis of variance (ANOVA), followed by Student-
Newman-Keuls post hoc test. Incremental area under the curve (AUC) for plasma glucose and 
insulin were calculated using GraphPad Prism. Groups of data were considered to be 
significantly different if p<0.05. All data is presented as mean ± S.E.M  
 
3. Results  
3.1. Effect of the hydrolysate on insulin release from BRIN‑BD11 cells 
The blue whiting protein hydrolysate generated with Alcalase 2.4L and Flavourzyme 500L 
induced a significant (p<0.001) augmentation of insulin release from BRIN-BD11 cells at 
concentrations ranging from 0.039 to 2.500 mg/mL (Fig 1a). A 3.8-fold increase in insulin 
secretion from BRIN-BD11 cells above the basal rate (5.6 mM glucose alone) was observed 
following incubation with 2.5 mg/mL of the blue whiting hydrolysate. As the hydrolysate was 
generated by direct hydrolysis of homogenised muscle it was not possible to compare this 
activity to that of an intact protein control sample. Incubation with the hydrolysate subjected 
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to SGID produced a significant (p<0.01 – p<0.001) stimulatory response at concentrations 
≥0.078 mg/mL (Fig 1b) with a 4.2-fold increase above the basal rate observed at a 
concentration of 2.5 mg/mL. No adverse effects on membrane integrity were observed at any 
of the hydrolysate concentrations tested (determined by lactate dehydrogenase assay, data not 
shown).  
   
3.2. Effect of hydrolysate on in vitro DPP-IV inhibition and GLP-1 release from GLUTag 
cells 
The hydrolysate was shown to inhibit DPP-IV activity in vitro (IC50: 1.28 ± 0.04 mg/mL, Table 
1). No significant difference in DPP-IV inhibitory activity was observed following SGID (IC50: 
1.49 ± 0.03 mg/mL, Table 1). A significant increase in GLP-1 release above the basal rate was 
observed following incubation of the cells with the hydrolysate (2.5 mg/mL, p<0.01, Fig 2) 
and the SGID sample (2.5 mg/mL, p<0.001, Fig 2). A significantly higher secretory response 
was observed following SGID of the hydrolysate (p<0.01). Lactate dehydrogenase assays 
indicated that none of the samples analysed were cytotoxic to the cells (data not shown). The 
basal secretion of GLP-1 from cultured GLUTag cells was increased significantly (p<0.001) in 
the presence of the positive control 10 mM L-glutamine and 2 mM glucose (Fig 2). 
 
3.3. Effect of hydrolysate on glucose uptake in 3T3-L1 adipocytes 
The hydrolysate (2.5 mg/mL) was shown to enhance both basal and insulin-stimulated glucose 
uptake in 3T3-L1 adipocytes (p<0.05 - 0.001, Fig 3). Interestingly, the hydrolysate alone 
augmented glucose uptake at a magnitude similar to 100 nM insulin. However, when combined 
with insulin (1 nM) the hydrolysate showed no further increase in glucose uptake compared to 
either hydrolysate alone or insulin alone. A similar result was observed with the hydrolysate 
subjected to SGID (Fig 3).  
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3.4. Effect of hydrolysate subjected to SGID on changes in membrane potential, 
intracellular Ca2+ and cAMP concentration in BRIN-BD11 cells 
A significant (6.4-fold increase; p<0.001, Fig 4a,c) increase in membrane depolarisation was 
observed in BRIN-BD11 cells in the presence of the hydrolysate which was subjected to SGID 
(2.5 mg/mL). However this effect was significantly lower than that mediated by the positive 
control 10mM KCl (9.5-fold increase, p<0.01, Fig 4c). The hydrolysate was also shown to 
cause a significant (p<0.001, Fig 4b,d) increase in intracellular calcium concentration 
compared to the glucose control. Interestingly, this increase was higher than that mediated by 
the positive control 10 mM alanine. In addition, the hydrolysate was shown to increase 
intracellular cAMP concentration in BRIN-BD11 cells (data not shown). 
 
3.5. Total and free amino acid analysis 
The total and free amino acid composition of the blue whiting hydrolysate subjected to SGID 
is shown in Table 2. Trp, was not determined and the sum of Glu and Gln and Asp and Asn are 
represented as Glx and Asx, respectively (Table 2). The blue whiting hydrolysate contains all 
essential amino acids with Leu and Lys accounting for 8.44 and 9.47% (w/w) of the total amino 
acids, respectively during total amino acid analysis. The most abundant amino acids found in 
the hydrolysate were Asx and Glx which represent 11.28 and 16.54% (w/w) of the total amino 
acids, respectively. Phe, Leu, His, Arg, Lys and Tyr are found in relatively high abundance in 
the free amino acid component of the hydrolysate, and account for 18.38, 11.60, 11.16, 11.13, 
9.71 and 8.26% (w/w) of the total free amino acid content (Table 2). The amino acid Phe was 
shown to be higher in the free amino acid complement than in the total amino acid complement 
(Table 2). The reason for this is unknown; however, it may be related to the use of two different 
methods for analysis of free and total amino acids. 
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3.6. Peptide identification 
A large number (309) of peptides were identified in the SGID of the blue whiting protein 
hydrolysate using database (Chordata limited SwissProt) and de novo sequencing approaches 
(Supplementary Tables 1 and 2). A total of 48 blue whiting protein sequences are available in 
the UniprotKB database. However, these sequences have not been reviewed thus making them 
potentially unreliable and are therefore not included in the SwissProt database. Therefore, only 
peptides with homology to proteins from other species were identified in the database search 
(Supplementary Table 1). The majority of the peptide sequences identified in this database 
search are homologous to contractile muscle proteins or associated muscle proteins including 
those involved in protein binding and filament/fibril assembly. Peptides and amino acids 
identified by de novo sequencing are reported in Supplementary Table 2. The majority of the 
peptide sequences identified by de novo sequencing show 100% homology to proteins derived 
from blue whiting (in-house database of 48 proteins) or proteins from closely related fish 
species including Merluccius merluccius, Danio rerio, Salmo salar and Triakis scyllium. 
 
3.7. Acute and persistent glucose-lowering effects of hydrolysate in normal mice 
Significantly lower blood glucose concentrations were observed in mice receiving the 
hydrolysate (100 mg/kg body weight) between 90 to 120 min (p<0.01) compared to animals 
receiving glucose alone (Fig 5A). Likewise, the integrated response of blood glucose, area 
under the curve (AUC), over 120 min in the mice was significantly lower (p<0.05) after 
administration of the hydrolysate compared to the control (Fig 5A). This reduction in glucose 
was corroborated with an overall improvement in insulin release in the treated mice (p<0.05; 
Supplementary Fig 1). The mice showed no visible adverse side effects following 
administration of the hydrolysate. The blue whiting protein hydrolysate was also shown to elicit 
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blood glucose lowering effects when administered 4 h (p<0.05, Fig 5B) prior to a glucose load 
in NIH Swiss mice. However, no such effects were observed 8 or 12 h after oral administration 
of the hydrolysate (Fig 5C).  
 
4. Discussion 
It is well established that dietary protein, protein hydrolysates, peptides and amino acids can 
beneficially regulate glycaemia through mechanisms such as direct stimulation of insulin 
secretion from pancreatic β-cell or indirectly through stimulation of the incretin hormone GLP-
1 which in turn acts as an insulin secretagogue in response to glucose (Newsholme & Krause, 
2012; Oseguera-Toledo et al., 2014). Results of in vitro studies show that the blue whiting 
protein hydrolysate generated herein stimulates the secretion of insulin and GLP-1 from 
cultured pancreatic β-cells and murine enteroendocrine GLUTag cells, respectively. This 
suggests that the hydrolysate may have the potential to stimulate the release of insulin from β-
cells by multiple mechanisms.  
The conditions used to generate protein hydrolysates, in particular the specificity of the 
enzyme(s) used and extent to which the protein is hydrolysed, can have a significant effect on 
the biological properties of the hydrolysate. Preliminary studies identified the conditions used 
for generation of the blue whiting hydrolysate herein were the optimum conditions for 
generation of a hydrolysate with high in vitro anti-diabetic activity. 
While previous studies have demonstrated the ability of a blue whiting protein hydrolysate to 
stimulate the secretion of GLP-1 in vitro from murine-derived enteroendocrine STC-1 cells 
(Cudennec et al., 2012), to the best of our knowledge this is the first report showing the in vitro 
insulinotropic potential of peptides derived from blue whiting muscle protein. Food protein-
derived hydrolysates such as those from dairy proteins have also been reported to stimulate 
insulin secretion from BRIN-BD11 cells (Gaudel et al., 2013; Nongonierma et al., 2013; 
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Power-Grant et al., 2015) and meat, milk, egg albumin, zein and rice derived hydrolysates have 
been shown to stimulate the release of GLP-1 from various cells grown in culture (Hira, 
Mochida, Miyashita, & Hara, 2009; Ishikawa et al., 2015; Power-Grant et al., 2015; Reimer, 
2006). It was not possible to directly compare the results presented herein with those published 
for insulin and GLP-1 secretory activity of other food-protein hydrolysates due to variations in 
assay conditions and the specific cell models used.  
Interestingly, the blue whiting-derived protein hydrolysate also inhibited DPP-IV in vitro (IC50: 
1.28 ± 0.04 mg/ml). DPP-IV is an ubiquitous enzyme expressed on the surface of most cell 
types which rapidly degrades GLP-1 in vivo (Green, Gault, O'Harte, & Flatt, 2004). Different 
strategies have been explored to aid glycaemic management in T2DM via increasing the half-
life of GLP-1, one of which includes the development of specific DPP-IV inhibitors. By 
inhibiting DPP-IV and stimulating GLP-1 release from endocrine cells, the blue whiting protein 
hydrolysate has shown potential to improve glycaemic control in TD2M subjects indirectly by 
increasing the level of biologically active GLP-1 circulating in the blood. In addition to 
improving insulin release from β-cells, enhanced GLP-1 concentrations lead to an increase in 
the synthesis of proinsulin and insulin in β-cells, elevate the differentiation of β-cell precursor 
cells, increase β-cell mass through increased proliferation and decrease β-cell apoptosis rate 
(Jakubowicz & Froy, 2013).   
If a peptide is to exert a systemic effect in vivo it must reach its target site in an intact form in 
adequate quantities. This event may be significantly hindered by the presence of various protein 
and/or peptide degrading enzymes located at different loci in the body, e.g., in the 
gastrointestinal tract, brush border membranes and blood plasma. Several SGID models have 
been devised to assess the digestibility of peptides and to provide an indication of the potential 
fate of proteins and peptides as they pass through the GI tract. The blue whiting hydrolysate 
herein was shown to retain both its DPP-IV inhibitory activity (IC50: 1.49 ± 0.03 mg/ml) and 
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its ability to stimulate the release of insulin from BRIN-BD11 cells following SGID, while the 
GLP-1 secretory activity mediated by the hydrolysate increased post SGID. The protein 
equivalent content of the hydrolysate and the hydrolysate subjected to SGID was determined 
to be ~ 86% (w/w). The results of physicochemical characterisation analyses (% DH and 
molecular mass distribution analysis, Table 1; Reversed phase ultra-performance liquid 
chromatography profiles (data not shown)) indicate that certain peptides in the hydrolysate 
were further degraded following SGID. As shown in Table 1 there was a significant increase 
in % DH following SGID and an increase in the quantity of peptides <0.5 kDa. The fact that 
the hydrolysate retained its DPP-IV inhibitory and insulinotropic activity, and that the GLP-1 
secretory activity increased following SGID would suggest that peptides in the original 
hydrolysate mediating the activity were resistant to degradation during SGID and/or additional 
lower molecular weight peptides were generated with similar, or, in the case of GLP-1 secretion 
higher activity. Furthermore, this indicates that the antidiabetic effect observed in vitro may 
translate in vivo.  
To test this hypothesis, the effect of the hydrolysate on glucose control was assessed in lean 
normal healthy mice. Interestingly, acute glucose-lowering effects were observed in mice 
following administration of the hydrolysate. The glucose elimination observed in treated mice 
corresponds to improved insulin release from beta cells, validating the direct insulinotropic 
activity (Supplementary Fig 1). Furthermore, the effects were still evident when the 
hydrolysate was administered 4 h prior to the glucose challenge. The fact that no 
antihyperglycemic effect was observed 8 or 12 h after oral administration of the hydrolysate 
indicates that the half-life of the hydrolysate in mice was between 4 and 8 h (Fig 6b). This is 
higher than the half-life observed for the antidiabetic meglitinide drugs (repaglinide and 
nateglinide) which reach peak plasma levels within 1 h of ingestion (Deruiter, 2003).  
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While a growing body of evidence supports the antidiabetic effect of food proteins, protein 
hydrolysates, peptides and amino acids, the mechanisms by which they exert their action 
remains unclear. It is believed that a modification in key insulinotropic amino acids in vivo and 
the release of incretin hormones are the primary regulators (Power-Grant et al., 2015). Research 
has shown that protein hydrolysates, peptides and amino acids such as Gln, Ala, Arg, Leu, Phe, 
Val, Ile, and Lys are strong insulin secretagogues (Dixon, Nolan, McClenaghan, Flatt, & 
Newsholme, 2003; Gaudel et al., 2013; Morifuji et al., 2010; Newsholme, Brennan, & Bender, 
2006; Nongonierma et al., 2013; Power-Grant et al., 2015). Furthermore, it has been 
demonstrated, that proteins, protein hydrolysates, peptides (Leu-Gly-Gly, Gly-Leu and Gly-
Pro) and amino acids such as Gln, Ala, Ser, Glu, Gly, Asn, Leu and Met can stimulate the 
release of GLP-1 from intestinal cells as well as  inhibit the enzyme involved in its degradation 
in vivo, DPP-IV (Cudennec et al., 2012; Diakogiannaki et al., 2013; Gameiro et al., 2005; 
Geraedts, Troost, Fischer, Edens, & Saris, 2011; Hira et al., 2009; Ishikawa et al., 2015; Power-
Grant et al., 2015; Reimann, Williams, da Silva Xavier, Rutter, & Gribble, 2004; Reimer, 
2006).  
Total and free amino acid and peptide identification analysis were performed on the 
hydrolysate subjected to SGID to determine which amino acid/peptides may potentially be 
associated with the antidiabetic activity observed in vitro and potentially that activity involved 
in vivo. Phe was the most abundant amino acid residue present in the free amino acid 
complement of the SGID sample at 18.38% (w/w) (Table 2). It is possible that the presence of 
this known insulin secretagogue, in addition to other insulin secretory residues such as Leu, 
Arg, Lys and Val, which are also present in relatively high quantities, may have contributed to 
the potent insulinotropic activity observed with this hydrolysate. The observed DPP-IV 
inhibitory and GLP-1 secretory activity exhibited by the hydrolysate may be associated with 
the presence of high/moderate quantities of free amino acids such as Phe, Arg and Tyr and Leu 
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and Met, which are known to inhibit DPP-IV (Neves, Harnedy, O’Keeffe, Alashi, et al., 2017; 
Neves, Harnedy, O’Keeffe, & FitzGerald, 2017) and stimulate GLP-1 secretion, respectively 
(Reimann et al., 2004) 
While a comprehensive list of short peptides with DPP-IV inhibitory activity and information 
with regard to the influence of certain structural features on such activity is available, 
information in relation to the sequence of peptides mediating insulin and GLP-1 stimulating 
activity is limited or non-existent. A number of dipeptides with known DPP-IV inhibitory 
activity were identified in the blue whiting hydrolysate. These include Trp-Leu, Trp-Ile, Leu-
Pro, Ile-Pro, Ala-Leu, Phe-Leu, Val-Arg, Leu-Trp, Ile-Leu and Leu-Leu (Connolly, O'Keeffe, 
Nongonierma, Piggott, & FitzGerald, 2017; Nongonierma, Mooney, Shields, & FitzGerald, 
2014). Furthermore, numerous peptides within the hydrolysate contain specific amino acids 
with known insulinotropic, GLP-1 stimulatory and DPP-IV inhibitory properties and these thus 
may be responsible for the antidiabetic activity observed in vitro and acute and persistent 
glucose lowering effect observed in normal lean mice. For example peptides such as Ala-Glu-
Arg-Glu, Glu-Gln-Glu-Glu, Ser-Gln, Glu-Glu, Glu-Ala, Glu-Ala-Glu, Glu-Ser-Ala, Ala-Glu-
Ala-Glu, Glu-Ser-Leu/Ile-Lys and Glu-Ala-Val contain amino acid residues with potent insulin 
and/or GLP-1 stimulating activity (Supplementary Table 2). These peptides may have 
contributed to both the potent insulinotropic and GLP-1 secretory activity observed with the 
hydrolysate. In addition to DPP-IV inhibitory activity, the peptide Leu-Leu also contains amino 
acids which are known to stimulate GLP-1 secretion. This peptide could potentially stimulate 
the release of GLP-1 and inhibit DPP-IV, the enzyme involved in its degradation, while Phe-
Leu, Val-Arg, Ile-Leu and Ile-Ile could potentially exhibit both insulinotropic and DPP-IV 
inhibitory activity. Leu-Leu may exhibit all three activities. However, peptide fractionation and 
bioactivity analysis with synthetic peptides would need to be performed in order to identify the 
peptides and/or amino acids responsible for the observed antidiabetic activity in vitro and in 
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vivo. It is also possible that the observed activity is a result of a synergistic effect mediated by 
a number of peptides or free amino acids or a combination of both.  
To investigate which cell signalling pathway may be involved in the insulin-releasing activity 
of the blue whiting hydrolysate subjected to SGID, and potentially that involved in vivo, the 
effects of the SGID sample on changes to membrane potential, intracellular [Ca2+] and cAMP 
production in BRIN-BD11 cells were investigated. The secretion of insulin from β-cells is 
primarily regulated by two signalling pathways, the KATP channel-dependent and KATP channel-
independent pathway (Henquin, 2000). In the former, the intracellular [ATP]/[ADP] ratio is 
increased leading to sequential closure of KATP channels, depolarization of the plasma 
membrane, opening of voltage-dependent calcium channels, influx of calcium and rapid 
activation of insulin exocytosis. The significant increase in both membrane depolarisation and 
intracellular calcium concentration following incubation with the hydrolysate suggest that the 
insulin secretion effects observed are likely to be mediated by the KATP channel-dependent 
pathway. The blue whiting protein hydrolysate also caused an increase in intracellular cAMP 
concentration with concomitant insulin release from BRIN-BD11 cells. This indicates that the 
hydrolysate may also mediate an insulin secretory response through the second messenger 
protein kinase A (PKA) pathway (Doyle & Egan, 2007). Furthermore, the 3T3-L1 adipocyte 
cells, is an excellent model exhibiting components of insulin receptor and signal transduction 
cascade, and is frequently used to evaluate insulin mediated glucose transport (Foyt, Ghazzi, 
Hanley, Saltiel, & Whitcomb, 2000). Our hydrolysates ability to improve glucose uptake could 
be due to its ability to stimulate GLUT4 receptor number and/or translocation  (Holman & 
Cushman, 1994; Simpson, Yver, & Hissin, 1983).  The molecular mechanisms underlying this 
blue whiting stimulated glucose uptake such as, phosphorylation of serine/threonine protein 
kinase Akt or AMP-activated protein kinase (AMPK) would need to be further elucidated 
(Shen et al., 2014). 
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4. Conclusion 
The results presented herein appear to be the first report showing that a blue whiting protein 
hydrolysate evokes multi-functional effects on markers of T2DM in vitro. This includes DPP-
IV inhibition and insulin secretion, GLP-1 release, and enhancement of both basal and insulin 
stimulated glucose uptake in BRIN-BD11, GLUTag and 3T3-L1 adipocyte cells, respectively. 
While, an antidiabetic effect has been observed in vivo in normal lean mice further studies are 
required to assess the effect of the hydrolysate in diabetic animal models and to identify the 
specific peptides and/or amino acids potentially responsible for the observed effects. Although 
the blue whiting hydrolysate has been shown to exert antidiabetic activity in both in vitro and 
in vivo animal studies, there is a need to undertake human intervention studies to assess its 
usefulness as a functional food ingredient for the prevention and management of T2DM. 
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Figure Legends 
 
 
 
 
                              
 
 
 
                                                                           
Figure 1: Effect of (a) a blue whiting (Micromesistius poutassou) protein hydrolysate and (b) its simulated gastrointestinal digestion (SGID) 
sample on insulin secretion from BRIN-BD11 cells. Values are expressed as mean  S.E.M. (n=6). **p< 0.01 and ***p<0.001 compared to 
respective glucose control (white bars, glucose alone). Grey bars: GLP-1 (10 µM). Black bars: hydrolysate/SGID sample. 
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Figure 2. Effect of a blue whiting (Micromesistius poutassou) protein hydrolysate and its simulated gastrointestinal digestion (SGID) sample on 
GLP-1 release from GLUTag cells. Values are expressed as mean ± SEM (n=3). **p<0.01, ***p<0.001 compared to glucose control, 
∆∆p<0.001compared to the blue whiting hydrolysate.  
 
 
 
 (2 ) 
  (  )  (  ) 
29 
 
 
                                       0
50
100
150
200
Control (no additions)
Apigenin (50 M)
Insulin (100 nM)
Insulin (1 nM)
Blue whiting hydrolysate alone (2.5 mg/ml)
Blue whiting hydrolysate (2.5 mg/ml) + Insulin (1 nM)
***
***
**
*** **
** *
F
lu
o
re
sc
en
c
e 
(R
el
at
iv
e 
u
n
it
s)
 
Figure 3: Effect of a blue whiting (Micromesistius poutassou) protein hydrolysate and its simulated gastrointestinal digestion (SGID) sample 
with /without insulin, on glucose uptake in 3T3-L1 adipocytes. Values are mean ± SEM (n=4). *p<0.05, **p<0.01 and ***p<0.001 compared to 
glucose-free media. 
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Figure 4: Effects of a blue whiting hydrolysate on β-cell signalling pathways. (A) membrane potential and (B) intracellular calcium in BRIN-
BD11 cells expressed as relative fluorescence units (RFU) and area under the curve (AUC, C, D). Values are mean ± SEM (n=6). ***p<0.001 
compared to 5.6 mM glucose control. ∆∆p<0.01 compared to positive control KCl (10 mM). 
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Figure 5: (A) Acute and (B and C) persistent effects of a blue whiting (Micromesistius poutassou) protein hydrolysate on glucose tolerance in 
normal mice. Blood glucose concentrations were measured before and after administration of glucose alone (18 mmol/kg) or in combination 
with the blue whiting hydrolysate (100 mg/kg). (B and C) Blue whiting hydrolysate (100 mg/kg) was administered (B) 4 h or (C) 8 and 12 h 
before glucose load (18 mmol/kg). Blood glucose area under the curve (AUC) values for 0–120 min post injection are also shown. Values are 
expressed as mean  S.E.M. (n=8). *p< 0.05 and **p< 0.01 compared to glucose alone.  
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Table 1. The degree of hydrolysis (DH), molecular mass distribution and dipeptidyl peptidase (DPP) IV inhibitory activity of a blue whiting 
(Micromesistius poutassou) protein hydrolysate and its simulated gastrointestinal digestion (SGID) sample. 
 
Test sample % DH Molecular mass distribution (% area) DPP-IV inhibition  
  >5 kDa 5-1 kDa 1-0.5 kDa <0.5 kDa IC50 (mg/ml) 
Hydrolysate 29.13 ± 0.18a 0.99 21.01 29.28 48.72 1.28 ± 0.04a 
Hydrolysate: SGID 32.58 ± 0.30b 0 7.30 28.15 64.55 1.49 ± 0.03a 
DH and DPP-IV inhibitory values for each sample with different subscript letters are significantly different at p<0.05. Values represent mean ± 
S.E.M (n=3). IC50: inhibitory concentration that inhibits enzyme activity by 50 % 
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Table 2. Total and free amino acid composition of a blue whiting (Micromesistius poutassou) 
protein hydrolysate subjected to simulated gastrointestinal digestion (SGID)  
Amino acid Total amino 
acids 
(g/100 g) 
 
Free amino 
acids 
(g/100 g) 
 
Met 1.82 0.58 
Thr 2.59 0.65  
Val 2.78 0.70 
Ile 2.74 0.43 
Leu 4.80 1.69 
Phe 2.31 2.67 
His 0.86 1.62 
Lys 5.39 1.41 
Trp - 0.23 
Cys 0.65 0.62 
Gly 2.78 0.12 
Tyr 1.87 1.20 
Arg 4.07 1.62 
Pro 2.02 nd 
Ser 2.55 0.28 
Asx 6.42 0.07 
Glx 9.41 0.21 
Ala 3.84 0.43 
All amino acids are referred by three letter code. -: not determined, nd: not detected 
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Supplementary Table 1 Peptides identified (with flanking N and C terminal residue) in a blue 
whiting (Micromesistius poutassou) protein hydrolysate subjected to simulated gastrointestinal 
digestion (SGID) using a database (UniprotKB/SwissProt, limited to Chordata) search. 
Peptide sequence Protein: Species  
(Accession number) 
Error 
(ppm) 
Mass/charge 
(m/z) 
z Retention time 
(min) 
R.VAPEEHPT.L Actin, alpha cardiac:  2 440.2148 2 5.91 
E.AGPSIVH.R Takifugu rubripes (P53480) 2.7 340.6908 2 8.23 
L.DSGDGVTH.N  -23.2 394.1553 2 4 
L.TEAPLNPK.A  -5 435.2378 2 8.03 
L.GEQIDN.L Myosin 13: Homo sapiens  -2.4 675.2928 1 5.24 
Q.GEVEDL.M (Q9UKX3) -6 661.2999 1 10.99 
M.GEQLDN.L Myosin heavy chain, cardiac 
muscle isoform: Gallus gallus 
(P29616) 
-2.4 675.2928 1 5.24 
F.TTGLE.A Tenascin-X: Homo sapiens  15.5 520.2693 1 11.78 
L.GLFPS.T (P22105) -16.8 520.2678 1 11.56 
G.GSGGT.I Shroom1: Homo sapiens  -39.8 378.1469 1 1.73 
L.GPGGD.R (Q2M3G4) 119.5 402.2098 1 48.06 
Y.YHTECVSGCVC.P Mucin-2: Homo sapiens 148 300.9119 4 48.68 
P.TCSNG.L  (Q02817) -24 481.1596 1 45.26 
E.APAAE.G Myristoylated alanine-rich C-
kinase substrate: Homo sapiens 
(P29966) 
0.8 458.2249 1 5.72 
V.AAAVP.A Anion exchange protein 3: 
Plecturocebus moloch 
(B1MTL0) 
-12 428.2452 1 8.63 
V.FDNSM.K Transformation/transcription 
domain-associated protein:  
Homo sapiens  (Q9Y4A5) 
1.5 613.2296 1 10.75 
E.VPVYE.N PYM homolog 1 exon junction 
complex-associated factor: Mus 
musculus (Q8CHP5) 
-1.9 606.3121 1 9.71 
N.GKGAE.K Inactive ubiquitin-specific 
peptidase 53: Mus musculus 
(P15975) 
-36.8 461.2185 1 5.41 
L.VAFPS.S DNA polymerase alpha 
holoenzyme-associated protein 
P1:Mus musculus (P25206) 
-14.1 520.2692 1 11.54 
P.AAHVY.P Eukaryotic translation initiation 
factor 4 gamma 1: Homo 
sapiens (Q04637) 
17 280.6497 2 5.06 
V.FDEDK.P Transforming acidic coiled-coil-
containing protein 2:  Mus 
musculus (Q9JJG0) 
-56.4 653.2409 1 7.5 
V.MEESH.V Calcium-binding and spermatid-
specific protein 1: Mus 
musculus (Q8C633) 
124.4 632.313 1 12.25 
G.TTLPGA.C Keratin, type I microfibrillar: 
Ovis aries (P25690) 
-22.5 559.296 1 10.12 
K.FEANP.E Uncharacterized protein 
C14orf37 homolog : Bos taurus 
(Q2TA21) 
-84 577.2132 1 2.83 
ppm: mass error, calculated as 106 × (experimental mass - theoretical mass) / theoretical mass 
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Supplementary Table 2: Peptides identified in a blue whiting (Micromesistius poutassou) 
protein hydrolysate subjected to simulated gastrointestinal digestion (SGID) by de novo 
sequencing. 
Peptide 
sequence 
ALC (%) Mass/charge 
(m/z) 
z Retention time 
(min) 
Error 
(ppm) 
Homologous Protein: 
Species (% homology) 
SADDIK 98 324.6587 2 4.61 -15.1 
Parvalbumin beta 3: 
Merluccius 
merluccius (100%) 
L/IDDL/I 97 475.2313 1 10.35 -18 - 
ADDL/IK 96 281.1454 2 3.95 -7.9 - 
VDVE 96 461.2186 1 6.45 -12.1 - 
L/IGME 95 449.2023 1 8.55 -9.3 - 
L/IDQDK 95 309.653 2 3.01 -17 - 
AGPS 95 331.1562 1 2.12 -15.2 - 
AAEDR 95 281.1331 2 1.65 -6.7 - 
AERE 94 252.6216 2 1.36 -10.5 
Rhodopsin (Fragment): 
Micromesistius poutassou 
(100%) 
AGL/IL/I 93 373.2388 1 12.41 -15.4 - 
VAL/IQ 93 430.259 1 7.19 -16.3 - 
QDWPR 92 351.161 2 3.88 -31.2 - 
SEL/IK 91 238.6373 2 3.32 -8.6 - 
EGDL/IGA 90 281.1458 2 3.82 58.5 - 
MEESH 90 632.3138 1 12.42 125.8 - 
LLEE 90 503.2628 1 7.62 -16.6 - 
DIDL 90 475.2332 1 13.02 -14 
Leucine-rich repeat and 
WD repeat-containing 
protein (Fragment): 
Micromesistius poutassou 
(100%) 
VPVYE 90 606.3121 1 9.71 -1.9 - 
L/IDVE 89 475.2319 1 10.42 -16.7 - 
PSDL/IL/I 89 544.3312 1 16.84 61.7 - 
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TDWTK 89 325.6516 2 1.47 -28.4 - 
AAHVY 89 280.6497 2 5.06 17 - 
GEVEDL/I 89 661.2999 1 10.99 -6 n.a. 
SSLE 89 435.2104 1 5.31 4.4 - 
LIPV 88 441.3003 1 13.91 -15.5 
ATP synthase subunit a: 
Micromesistius poutassou 
(100%) 
FDEDQ 88 653.2409 1 7.5 -0.6 - 
GDL/IK 87 216.624 2 3.02 -10.5 - 
VDTAGPA 87 315.6718 2 4.43 43 n.a. 
ESL/IK 87 238.6381 2 3.52 -5.2 - 
L/ISDL/I 87 447.2383 1 9.86 -14.9 - 
FVL/ID 86 493.2663 1 13.39 1.3 - 
AGSP 86 331.1559 1 2.18 -16 - 
YNEL/I 86 538.25 1 9.74 -1.4 - 
VLVA 86 401.2686 1 9.1 -17.9 
Cytochrome b: 
Micromesistius poutassou 
(100%) 
VIVA      
Leucine-rich repeat and 
WD repeat-containing 
protein (Fragment): 
Micromesistius poutassou 
(100%) 
AGPSLVH 86 340.6908 2 8.23 2.7 
Isoform 2 of Allantoicase: 
Danio rerio (87.5%) 
L/IV 85 231.168 1 5.58 -10 Numerous (100%) 
DSGDGVTH 84 394.1553 2 4 -23.2 
Actin, cytoplasmic 1: 
Danio rerio  (100%) 
KL/I 84 260.1564 1 2.44 -156.2 Numerous (100%) 
GSLL 84 389.2386 1 11.99 -2.2 
Cytochrome b: 
Micromesistius poutassou 
(100%) 
GSLI      
Cytochrome c oxidase 
subunit :1 Micromesistius 
poutassou (100%) 
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SL/I 84 219.1314 1 4.31 -11.7 Numerous (100%) 
VLEL 83 473.2891 1 10.26 -16.6 
NADH-ubiquinone 
oxidoreductase chain 6: 
Micromesistius poutassou 
(100%) 
SADDAGL/I 83 324.6595 2 4.79 43.8 n.a. 
VDTAPK 83 315.6706 2 4.35 -18.9 n.a. 
GSL/IE 82 405.1916 1 5.12 -15.8 - 
R 82 175.1167 1 1.03 -13 Numerous (100%) 
EA 82 219.0947 1 1.09 -13.1 Numerous (100%) 
ER 82 304.1558 1 1.02 -18.8 Numerous (100%) 
EM 82 279.0972 1 2.63 -13.4 
NADH-ubiquinone 
oxidoreductase chain 4: 
Micromesistius poutassou 
(100%) 
EF 82 295.1248 1 7.05 -13.5 Numerous (100%) 
AGDDAPR 82 351.1641 2 3.92 -0.4 
Actin, cytoplasmic 1: 
Salmo salar (100%) 
ET 82 249.1052 1 1.09 -11.7 Numerous (100%) 
TE 82 249.1047 1 1.13 -13.6 Numerous (100%) 
QEL/I 82 389.1992 1 7.79 -10 Numerous (100%) 
L/IMFE 82 539.2584 1 13.92 9.4  
EE 82 277.1001 1 1.23 -10.4 Numerous (100%) 
L/IVDTAPK 81 372.2174 2 6.55 -2.9 n.a. 
VY 81 281.1459 1 5.2 -13 Numerous (100%) 
EAE 81 348.1337 1 1.68 -18.5 - 
VEEE 81 505.2144 1 3.85 0.8 - 
EL/IQ 81 389.1962 1 3.72 -17.7 - 
EVDL/IR 81 316.1708 2 9.5 -10.6 - 
NNDL/IR 81 316.1714 2 9.45 31.3 - 
L/IEEL/I 81 503.273 1 11.28 3.7 - 
VAFP 81 433.2373 1 13.12 -16.8 - 
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KS 81 234.1122 1 1.05 -139.9 Numerous (100%) 
AEL/IE 81 461.2164 1 6.33 -17 - 
TDACAGNE 81 390.6751 2 4.61 77 n.a. 
TEE 80 378.1459 1 1.61 -12.7 - 
W 80 205.1241 1 6.87 131.9 Numerous (100%) 
Y 80 182.0803 1 2.57 -5 Numerous (100%) 
EK 80 276.1513 1 5.92 -14.7 Numerous (100%) 
L/IDFE 80 523.2411 1 12.4 2.5 - 
TEAPL/INPK 80 435.2378 2 8.03 -5 
Actin, cytoplasmic 2: 
Triakis scyllium (100%) 
F 80 166.0839 1 4.04 -13.9 Numerous (100%) 
C 80 122.0562 1 4.09 240.8 Numerous (100%) 
L/IADL/I 79 431.241 1 12.74 -20.9 - 
SADDSGP 79 324.6599 2 4.72 101.2 n.a. 
EDE 79 392.1238 1 1.56 -15.7 - 
VL/IEN 79 474.2563 1 4.66 1.1 - 
EVDL/I 79 475.2339 1 12.94 -12.4 - 
ELE 79 390.1794 1 5.06 -19.8 
Leucine-rich repeat and 
WD repeat-containing 
protein (Fragment): 
Micromesistius poutassou 
(100%) 
EGL/IA 79 389.1979 1 5.91 -13.3 - 
SVVN 79 418.2243 1 4.82 -12.8 - 
DSGDRTH 79 394.1601 2 4.07 -25.3 n.a. 
EGDL/IK 79 281.1423 2 3.9 -18.8 - 
AL/IPH 79 219.1268 2 5.86 -10.1 - 
TDLK 79 238.6369 2 3.31 -10.6 
NADH-ubiquinone 
oxidoreductase chain 4: 
Micromesistius poutassou 
(100%) 
NGL/IE 79 432.2021 1 4.99 -15.8 - 
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SL/IPL/INPK 79 384.7163 2 6.97 -47 n.a. 
DL/IWA 79 252.6356 2 4.68 37.1 - 
EAV 78 318.1642 1 4.64 -5.5 
Cytochrome c oxidase 
subunit 2: Micromesistius 
poutassou (100%) 
TDHTMT 78 353.1704 2 4.42 65.7 n.a. 
LDL 78 360.2086 1 12.21 -12 Numerous (100%) 
LDI      Numerous (100%) 
IDL      
Leucine-rich repeat and 
WD repeat-containing 
protein (Fragment): 
Micromesistius poutassou 
(100%) 
NWGPL/I 78 293.6605 2 7.43 26.1 - 
L/IL/I 78 245.1824 1 9.43 -14.4 Numerous (100%) 
NGAE 78 390.1802 1 5.01 46.9 - 
ADL/IA 78 389.1973 1 5.98 -14.8 - 
GQNPTNTR 78 444.2146 2 3.9 -12.5 
Cysteine-rich DPF motif 
domain-containing protein 
1: Danio rerio (75%) 
KH 78 284.1296 1 0.95 -148.7 - 
QDVPNE 78 351.1602 2 3.82 4.2 n.a. 
L/IQL/IE 77 502.2884 1 10.42 2.5 - 
RL/I 77 288.1883 1 9.67 -51.2 Numerous (100%) 
MDL/IE 77 507.2119 1 10.1 0 - 
QPSL/IVH 77 340.6868 2 8.28 -9.3 n.a. 
VL/IDENK 77 359.1952 2 4.37 7.5 n.a. 
LLE 77 374.2222 1 7.18 -17 Numerous (100%) 
LIE      
NADH-ubiquinone 
oxidoreductase chain 1: 
Micromesistius poutassou 
(100%) 
IIE      Numerous (100%) 
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ILE      
NADH-ubiquinone 
oxidoreductase chain 5: 
Micromesistius poutassou 
(100%) 
LF 77 279.166 1 11.18 -15.5 Numerous (100%) 
VAFPS 77 520.2692 1 11.54 -14.1 - 
LVL 77 344.2469 1 12.97 -21.6 Numerous (100%) 
IVL      Numerous (100%) 
LVI      Numerous (100%) 
L/IEE 77 390.1801 1 5.31 -18.1 - 
DDL 77 362.1497 1 6.14 -16.7 
Leucine-rich repeat and 
WD repeat-containing 
protein (Fragment): 
Micromesistius poutassou 
(100%) 
SLL 77 332.2125 1 11.77 -16.5 Numerous (100%) 
SIL      Numerous (100%) 
SLI      Numerous (100%) 
SII      
NADH-ubiquinone 
oxidoreductase chain 5: 
Micromesistius poutassou 
(100%) 
DLE 77 376.1661 1 5.16 -14.2 
NADH-ubiquinone 
oxidoreductase chain 3: 
Micromesistius poutassou 
(100%) 
DIE      Numerous (100%) 
L/ISFL/ISE 77 348.1716 2 4.64 -36.1 n.a. 
LEL 77 374.2194 1 12.78 -24.5 Numerous (100%) 
LEI      Numerous (100%) 
IEI      Numerous (100%) 
VDL 77 346.1868 1 9.86 -30.2 Numerous (100%) 
VDI      
Pannexin 2 (Fragment): 
Micromesistius poutassou 
(100%) 
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SQ 77 234.104 1 1.1 -19 Numerous (100%) 
L/IDE 77 376.164 1 4.85 -19.8 - 
AEAE 77 419.1719 1 2.03 -12.7 - 
DL/I 76 247.1256 1 5.09 -13.3 Numerous (100%) 
VQL/IE 76 488.2688 1 8.73 -5.4 - 
TY 76 283.0984 1 4.17 -108 Numerous (100%) 
L/IEEDE 76 634.2645 1 5.34 12.4 - 
WL/I 76 318.1987 1 9.24 55 Numerous (100%) 
APESETF 76 390.6805 2 4.61 16.4 n.a. 
YPL/IE 76 521.2601 1 10.26 -1 - 
ES 76 235.0895 1 1.13 -12.6 Numerous (100%) 
DASQGK 76 303.1445 2 1.33 -11.9 n.a. 
EW 76 334.1761 1 8.92 109.2 Numerous (100%) 
EL/I 76 261.1408 1 5.4 -14.1 Numerous (100%) 
AL/IL/I 76 316.2187 1 11.72 -13.8 Numerous (100%) 
L/IAL/I 76 316.2184 1 11.78 -14.9 Numerous (100%) 
L/IE 76 261.1413 1 3.15 -12.2 Numerous (100%) 
RM 76 306.1442 1 6.62 -49.8 Numerous (100%) 
L/ISE 76 348.1709 1 4.73 -16.2 - 
AEL 76 332.1771 1 7.16 -13.6 Numerous (100%) 
SF 76 253.1155 1 5.99 -11.1 Numerous (100%) 
L/ID 76 247.1251 1 2.68 -15 Numerous (100%) 
TF 75 267.1292 1 6.54 -17.7 Numerous (100%) 
MEEVH 75 644.3062 1 14.16 55 - 
ETE 75 378.1472 1 1.68 -9.3 - 
SL/IE 75 348.1708 1 4.78 -16.6 - 
TEAPL/IKPN 75 435.2348 2 7.65 -11.9 n.a. 
TVT 75 320.178 1 3.77 -11.3 Numerous (100%) 
L/IEQ 75 389.1982 1 3.94 -12.5 - 
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L/IW 75 318.1754 1 12.14 -18.2 Numerous (100%) 
LVE 75 360.2072 1 5.59 -16 
Leucine-rich repeat and 
WD repeat-containing 
protein (Fragment): 
Micromesistius poutassou 
(100%) 
LAE 75 332.1775 1 4.6 -12.5 Numerous (100%) 
AL/I 75 203.1332 1 4.4 -28.7 Numerous (100%) 
L/IFAG 75 407.188 1 10.55 -100.7 - 
L/IN 75 246.1413 1 1.95 -14.5 Numerous (100%) 
VL/I 75 231.1669 1 7.16 -14.7 Numerous (100%) 
VEEL/I 75 489.2566 1 9.81 2.3 - 
L/IK 75 260.1919 1 1.51 -19.2 Numerous (100%) 
AADE 75 405.1766 1 1.57 37.1 - 
NL/I 75 246.1389 1 5.73 -24.1 Numerous (100%) 
AAL 75 274.1718 1 6.68 -15.7 Numerous (100%) 
L/IM 75 263.139 1 6.91 -13 Numerous (100%) 
TL/I 75 233.1453 1 5.25 -18.6 Numerous (100%) 
FL/IE 74 408.2083 1 9.35 -11.3 - 
L/IR 74 288.1972 1 3.09 -20.3 Numerous (100%) 
VAL/I 74 302.2041 1 9.91 -10.9 Numerous (100%) 
L/IQ 74 260.1567 1 2.48 -14.5 Numerous (100%) 
ADE 74 334.122 1 1.34 -7.5 - 
L/IY 74 295.1627 1 7.31 -8.7 Numerous (100%) 
FE 74 295.124 1 5.13 -16.4 Numerous (100%) 
L/IT 74 233.1464 1 2.53 -13.6 Numerous (100%) 
LDA 74 318.1624 1 5.18 -11.2 
NADH-ubiquinone 
oxidoreductase chain 4L: 
Micromesistius poutassou 
(100%) 
FIEEED 74 781.3235 1 9.59 -2 
Parvalbumin beta 4 
(Fragments): Merluccius 
merluccius (100%) 
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ADTCEL/IE 74 390.6752 2 4.67 45.1 n.a. 
SAL/I 74 290.1682 1 5.78 -9.6 Numerous (100%) 
QDDAVGP 74 351.1605 2 3.93 5.2 n.a. 
ALQ 74 331.1925 1 3.64 -15.3 Numerous (100%) 
L/IH 74 269.1573 1 2.07 -13.2 Numerous (100%) 
YL/I 74 295.1599 1 8.73 -18 Numerous (100%) 
AVL/I 74 302.2044 1 9.28 -9.9 Numerous (100%) 
FL/I 74 279.1674 1 12.26 -10.2 Numerous (100%) 
AVVL/I 74 401.2691 1 14.48 -16.8 - 
L/IDSM 74 465.2018 1 7.51 1 - 
VLT 74 332.212 1 5.7 -18.1 
Cytochrome b: 
Micromesistius poutassou 
(100%) 
VIT      Numerous (100%) 
ASL 74 290.1671 1 6.46 -13.6 Numerous (100%) 
ASI      
NADH-ubiquinone 
oxidoreductase chain 2: 
Micromesistius poutassou 
(100%) 
IAQ 74 331.1938 1 3.7 -11.6 
Leucine-rich repeat and 
WD repeat-containing 
protein (Fragment): 
Micromesistius poutassou 
(100%) 
AEE 73 348.1359 1 1.58 -12.3 - 
ESE 73 364.1279 1 1.44 -19.6 Numerous (100%) 
QL/I 73 260.1567 1 4.94 -14.5 Numerous (100%) 
ED 73 263.1382 1 8.57 194.2 Numerous (100%) 
ML/I 73 263.1383 1 8.53 -15.5 Numerous (100%) 
NLE 73 375.1846 1 3.47 -7.5 
Rhodopsin (Fragment): 
Micromesistius poutassou 
(100%) 
ETA 73 320.1407 1 1.76 -14.3 - 
DF 73 281.0919 1 10.61 -75.9 Numerous (100%) 
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FAYF 73 547.2391 1 2.74 -29.2 - 
DY 73 297.0858 1 5.97 -75.3 Numerous (100%) 
VE 73 247.1248 1 1.72 -16.5 Numerous (100%) 
GL/IFPS 73 520.2678 1 11.56 -16.8 - 
APFDVK 73 338.6841 2 8.09 -8.1 n.a. 
L/IVML/INQ 73 359.1901 2 4.44 -32.8 n.a. 
NQFL/IEE 73 390.1831 2 4.96 2.6 n.a. 
L/IA 73 203.1365 1 3.51 -12.2 - 
QLL 73 373.236 1 12.45 -22.8 Numerous (100%) 
YVE 73 410.1884 1 5.47 -9.3 - 
L/IDDANTL/I 73 381.1978 2 6.04 27.3 n.a. 
AAE 72 290.132 1 1.28 -9.2 Numerous (100%) 
TDY 72 398.1485 1 5.35 -18.2 Numerous (100%) 
SGL/IE 72 405.1907 1 5.17 -18 - 
VVE 72 346.1919 1 4.19 -15.6 
Cytochrome c oxidase 
subunit 2: Micromesistius 
poutassou (100%) 
LNN 72 360.1913 1 10.35 9.8 Numerous (100%) 
SDIE 72 463.2045 1 5.62 2.3 Numerous (100%) 
VDDL/I 72 461.2313 1 8.89 15.5 - 
VEA 72 318.1646 1 3.2 -4.3 Numerous (100%) 
AE 72 219.095 1 1.24 -11.4 Numerous (100%) 
STM 72 338.1341 1 3.67 -11.8 Numerous (100%) 
VGDQ 72 418.1961 1 3.04 6.9 - 
YE 72 311.1209 1 3.03 -9.1 Numerous (100%) 
VLE 72 360.2084 1 5.72 -12.6 
NADH-ubiquinone 
oxidoreductase chain 6: 
Micromesistius poutassou 
(100%) 
DE 72 263.1385 1 7.36 195.1 Numerous (100%) 
VQ 72 246.1407 1 1.48 -16.7 Numerous (100%) 
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CE 72 250.9702 1 2.17 -397.7 Numerous (100%) 
SDE 72 350.1156 1 1.26 -10.8 - 
EQEE 72 534.2025 1 2.41 -3.1 - 
L/IKDQPED 72 422.7047 2 6.14 -3.1 n.a. 
VDY 72 396.1693 1 7.48 -18.2 Numerous (100%) 
YM 71 313.1172 1 6.32 -14.1 Numerous (100%) 
AL/IFL/IAE 71 332.1767 2 4.9 -37.8 - 
FEL/IHC 71 648.2693 1 6.87 -18 - 
L/IP 71 229.1521 1 6.85 -11.2 Numerous (100%) 
AL/IM 71 334.1741 1 8.81 -16.3 Numerous (100%) 
EV 71 247.1252 1 2.55 -14.6 Numerous (100%) 
EN 71 262.1303 1 0.94 103.4 Numerous (100%) 
VW 71 304.1609 1 10.25 -15.3 Numerous (100%) 
FQ 71 294.1405 1 4.16 -14.7 Numerous (100%) 
ME 71 279.0976 1 2.53 -11.8 Numerous (100%) 
AM 71 221.0925 1 2.75 -13.2 Numerous (100%) 
ST 71 207.0936 1 1.07 -18.9 Numerous (100%) 
VL/IEM 71 491.2521 1 10.7 -2.7 - 
AW 71 276.1296 1 8.53 -16.9 Numerous (100%) 
DAT 71 306.125 1 1.3 -15 Numerous (100%) 
MQ 71 278.1147 1 1.9 -7.9 Numerous (100%) 
ADDL/IAWGA 71 409.7 2 5.39 30.3 n.a. 
VT 71 219.1305 1 1.47 -15.7 Numerous (100%) 
VV 71 217.149 1 3.96 -26 Numerous (100%) 
AF 71 237.1204 1 6.42 -12.3 Numerous (100%) 
VVDL/I 71 445.264 1 11.84 -3.8 - 
ADT 71 306.1277 1 1.39 -5.9 - 
AY 71 253.1149 1 3.78 -13.2 Numerous (100%) 
FN 71 280.1239 1 3.54 -19 Numerous (100%) 
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VAPFEFVA 70 440.2144 2 6.09 -45.1 n.a. 
MF 70 297.1228 1 10.66 -13.2 Numerous (100%) 
AR 70 246.1781 1 1.15 90 Numerous (100%) 
SY 70 269.0915 1 3.62 -81 Numerous (100%) 
DL/IAG 70 375.1824 1 5.28 -13.4 - 
PSPH 70 219.1258 2 5.72 68.8 - 
L/IDTDY 70 626.2632 1 10.83 -5.8 - 
AK 70 218.1464 1 0.81 -16.3 Numerous (100%) 
VGNE 70 418.1919 1 2.99 -3.2 - 
AGDE 70 391.1453 1 1.43 -1.8 - 
APEHETP 70 390.6732 2 4.56 -16.9 n.a. 
VAPESGCCN 70 440.2148 2 5.91 101.2 n.a. 
TV 70 219.1307 1 2.59 -15 Numerous (100%) 
SSSL/IE 70 522.2406 1 5.55 0.1 - 
MY 70 313.1162 1 6.39 -17.3 Numerous (100%) 
VASL 70 389.1997 1 6.93 -102.5 - 
YQ 70 310.1363 1 2.45 -11.2 Numerous (100%) 
ESA 70 306.1237 1 1.54 -19.1 - 
VM 70 249.1239 1 4.77 -11.6 Numerous (100%) 
HQ 70 284.1281 1 0.99 -25.4 Numerous (100%) 
MEPE 70 505.2127 1 8.12 32.5 - 
VR 70 274.185 1 1.19 -8.5 Numerous (100%) 
CSRPV 70 281.1449 2 5.42 2.1 - 
VL/IDSM 70 564.2707 1 9.9 1.6 - 
VF 70 265.1772 1 44.3 85.2 Numerous (100%) 
Residues in bold typeface indicate homology. 
ALC: Average local confidence is an average of the individual local confidence score for each amino 
acid and is based on the PEAKS algorithm (Ma et al., 2003).  
L/I: The sequence maybe L or I. 
ppm: mass error, calculated as 106 × (experimental mass - theoretical mass) / theoretical mass. 
n.a.: peptides ≥ 6 amino acids did not show homology with proteins from a species within phylum 
Chordata following Blast analysis using FASTAM tool. 
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 - : peptides <5 amino acids did not show homology with the 48 protein sequences of blue whiting 
(Micromesistius poutassou) in the ‘in-house’ database. 
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Supplementary Figure 1: Acute insulin-releasing effects of a blue whiting (Micromesistius 
poutassou) protein hydrolysate following oral administration (100 mg/kg body weight) together 
with glucose (18 mmol/kg). (A) Plasma insulin response in normal overnight fasted mice. (B) 
Plasma insulin area under the curve (AUC) values for 0 to 120 min post-gavage are also shown. 
Values represent mean ± SEM for eight mice (n=8). *p<0.05 compared to glucose alone.  
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